Published in Nat Rev Neurol on June 01, 2009
The heterogeneity of non-motor symptoms of Parkinson's disease. Neurol Sci (2014) 1.42
Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophr Bull (2014) 1.32
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling. Cell Rep (2014) 1.11
Pareidolias: complex visual illusions in dementia with Lewy bodies. Brain (2012) 1.11
What visual illusions teach us about schizophrenia. Front Integr Neurosci (2014) 1.09
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology (2009) 1.02
Parallel basal ganglia circuits for voluntary and automatic behaviour to reach rewards. Brain (2015) 1.01
The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull (2012) 1.00
Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management. Front Neurol (2012) 0.98
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Psychiatric issues in cognitive impairment. Mov Disord (2014) 0.91
The default mode network is disrupted in Parkinson's disease with visual hallucinations. Hum Brain Mapp (2014) 0.90
Treatment of psychosis and dementia in Parkinson's disease. Curr Treat Options Neurol (2014) 0.89
A synthesis of evidence on inhibitory control and auditory hallucinations based on the Research Domain Criteria (RDoC) framework. Front Hum Neurosci (2014) 0.88
Hallucinations: A Systematic Review of Points of Similarity and Difference Across Diagnostic Classes. Schizophr Bull (2016) 0.87
The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J Neurol (2011) 0.87
Feeling of presence in Parkinson's disease. J Neurol Neurosurg Psychiatry (2011) 0.85
Feasibility of a web-based survey of hallucinations and assessment of visual function in patients with Parkinson's disease. Interact J Med Res (2014) 0.81
Cognitive phenotype of psychotic symptoms in Alzheimer's disease: evidence for impaired visuoperceptual function in the misidentification subtype. Int J Geriatr Psychiatry (2015) 0.80
Multi-modal hallucinations and cognitive function in Parkinson's disease. Dement Geriatr Cogn Disord (2010) 0.80
Are patients with Parkinson's disease blind to blindsight? Brain (2014) 0.79
Molecular heterogeneity of midbrain dopaminergic neurons - Moving toward single cell resolution. FEBS Lett (2015) 0.78
On visual hallucinations and cortical networks: a trans-diagnostic review. J Neurol (2015) 0.77
Advances in the treatment of visual hallucinations in neurodegenerative diseases. Future Neurol (2013) 0.77
Neural and behavioral substrates of subtypes of Parkinson's disease. Front Syst Neurosci (2013) 0.76
The psychosis spectrum in Parkinson disease. Nat Rev Neurol (2017) 0.75
Fifty Percent Prevalence of Extracampine Hallucinations in Parkinson's Disease Patients. Front Neurol (2015) 0.75
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. J Neurol Neurosurg Psychiatry (2017) 0.75
Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat (2017) 0.75
Hallucinations and conscious access to visual inputs in Parkinson's disease. Sci Rep (2016) 0.75
Visual dysfunction in Parkinson's disease. Brain (2016) 0.75
Structural and Functional Neuroimaging of Visual Hallucinations in Lewy Body Disease: A Systematic Literature Review. Brain Sci (2017) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat Rev Neurosci (2008) 3.61
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol (2005) 2.94
Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med (1999) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat Rev Neurosci (2002) 2.69
Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet (1996) 2.67
Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst (1972) 2.64
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc (2000) 2.38
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain (2000) 2.23
Clinical phenotype of Parkinson disease dementia. Neurology (2006) 2.22
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Visual hallucinations associated with Parkinson disease. Arch Neurol (1996) 2.06
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Impaired visual search in drivers with Parkinson's disease. Ann Neurol (2006) 2.03
The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci (1998) 2.01
Hypocretin (orexin) loss in Parkinson's disease. Brain (2007) 1.98
REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology (2007) 1.95
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 1.85
Dopaminergic control of sleep-wake states. J Neurosci (2006) 1.77
Risk factors for nursing home placement in advanced Parkinson's disease. Neurology (1993) 1.76
Cognitive performance in REM sleep behaviour disorder: a possible early marker of neurodegenerative disease? Sleep Med (2007) 1.72
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease. Brain (2005) 1.71
Retinal nerve fiber layer thinning in Parkinson disease. Vision Res (2004) 1.67
Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci (2005) 1.65
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol (2005) 1.61
Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord (2004) 1.59
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology (1998) 1.58
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
Psychiatric symptoms and syndromes in Parkinson's disease. Am J Psychiatry (1951) 1.53
Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol (1999) 1.49
Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology (2002) 1.42
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Update on the pharmacology of REM sleep behavior disorder. Neurology (2006) 1.41
The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol (1999) 1.39
Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res (1997) 1.39
Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology (2004) 1.38
Impaired navigation in drivers with Parkinson's disease. Brain (2007) 1.33
A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry (2001) 1.26
Facial expression recognition in people with medicated and unmedicated Parkinson's disease. Neuropsychologia (2003) 1.23
Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry (2001) 1.21
Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci (1990) 1.20
Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord (2005) 1.20
Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol (2000) 1.20
A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord (2007) 1.20
Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry (1978) 1.17
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology (2001) 1.16
Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. Neuropsychologia (2006) 1.15
Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 1.14
Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol (1993) 1.13
Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology (2003) 1.12
Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol (1982) 1.11
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Clin Pract Neurol (2007) 1.11
Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord (2007) 1.10
Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology (2004) 1.10
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry (2004) 1.09
Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord (2004) 1.08
Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry (2007) 1.07
Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry (2006) 1.05
Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord (2002) 1.05
Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology (2004) 1.05
Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology (2005) 1.00
Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol (2007) 0.99
Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 0.99
Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn (1995) 0.99
Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol (2006) 0.98
Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry (1982) 0.98
A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations. Mov Disord (2007) 0.98
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol (1998) 0.98
Hallucinations in Parkinson disease in the prelevodopa era. Neurology (2006) 0.98
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother (2008) 0.97
Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology (2007) 0.97
Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem (1990) 0.97
Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry (1998) 0.96
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol (2004) 0.95
Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia (2003) 0.95
Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci (2006) 0.95
Increased mortality among elderly patients with dementia using atypical antipsychotics. CMAJ (2005) 0.94
Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord (2007) 0.94
Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci (2002) 0.94
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology (2005) 0.93
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol (2006) 0.92
Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm (Vienna) (2004) 0.92
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol (2001) 0.92
Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann Neurol (2003) 0.92
Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord (2007) 0.90
New developments in the pathology of Parkinson's disease. Adv Neurol (1990) 0.90
Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord (2005) 0.90
Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat (1988) 0.90
Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int (2007) 0.90
Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord (2008) 0.89
Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol (2005) 0.88
Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol (2002) 0.88
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis (2007) 0.88
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain (2005) 1.57
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol (2005) 1.48
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
The origins of scientific cinematography and early medical applications. Neurology (2004) 1.39
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord (2011) 1.31
Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24
Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol (2003) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol (2012) 1.20
Dystonia rating scales: critique and recommendations. Mov Disord (2013) 1.17
Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord (2007) 1.16
Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2012) 1.15
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord (2006) 1.12
Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet (2009) 1.11
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord (2010) 1.09
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol (2004) 1.07
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord (2004) 1.05
Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord (2013) 1.05
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials (2005) 1.02
Movement disorders caused by medical disease. Semin Neurol (2009) 1.02
Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord (2009) 1.01
Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord (2014) 1.01
Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.99
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord (2009) 0.98
Hallucinations in Parkinson disease in the prelevodopa era. Neurology (2006) 0.98
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Neuroimaging of white matter in aging and dementia. Clin Neuropsychol (2007) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol (2004) 0.95
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol (2003) 0.95
Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord (2005) 0.94
Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord (2011) 0.93
Head tremor in Parkinson's disease. Mov Disord (2006) 0.91
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord (2010) 0.91
Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord (2011) 0.91
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord (2009) 0.90
Predicting white matter targets for direct neurostimulation therapy. Epilepsy Res (2010) 0.90
Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord (2013) 0.90
The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.90
Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One (2013) 0.89
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord (2009) 0.89
Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol (2007) 0.87
Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord (2011) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord (2012) 0.86
Hallucinations in Parkinson's disease: a follow-up study. Mov Disord (2005) 0.86
Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord (2003) 0.85
Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord (2005) 0.85
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord (2008) 0.84
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord (2009) 0.83
Disruption of cigarette smoking addiction after posterior cingulate damage. J Neurosurg (2010) 0.83
Clinical routine use of dopamine transporter imaging in 516 consecutive patients. J Neurol (2015) 0.82
Depression and coping as predictors of change after deep brain stimulation in Parkinson's disease. World Neurosurg (2011) 0.82
Tai chi for patients with Parkinson's disease. N Engl J Med (2012) 0.82
Assessing bradykinesia in parkinsonian disorders. Front Neurol (2013) 0.82
The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord (2011) 0.82
Spinal stimulation for movement disorders. Neurotherapeutics (2014) 0.81
Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord (2006) 0.81
Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord (2003) 0.81
Reversible chorea in association with Graves' disease and moyamoya syndrome. Mov Disord (2008) 0.80
Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia. Eur Neurol (2008) 0.80
Awareness of memory deficits in early stage Huntington's disease. PLoS One (2013) 0.80
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord (2014) 0.79